Mesenchymal stem cells for idiopathic pulmonary fibrosis

This trial examines the effect of administration of placenta-derived mesenchymal stem cells (MSCs) in patients with idiopathic pulmonary fibrosis (IPF). There was no acute infusional toxicity.